Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora 制药将出席 Citizens JMP 生命科学会议
May 08, 2024 7:00am EDT Download as PDF
美国东部时间 2024 年 5 月 8 日上午 7:00 以 PDF 格式下载
Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14th, 2024 at 1:00 pm EDT.
加利福尼亚州恩西尼塔斯--（Newsfile Corp.，2024年5月8日）——Kiora Pharmicals（纳斯达克股票代码：KPRX）邀请投资者在5月14日星期二的Citizens JMP生命科学会议上观看公司的在线演讲第四，2024 年美国东部时间下午 1:00。
Kiora's presentations can be accessed live from the homepage of the investor relations section on Kiora's website (ir.kiorapharma.com) and will be available for replay for 90 days on the investor relations "events" page.
Kiora的演示可以从主页上实时观看 投资者关系 Kiora 网站上的栏目 (ir.kiorapharma.com），并将在投资者关系 “活动” 页面上重播90天。
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
关于 Kiora 制药
Kiora Pharmaceuticals是一家临床阶段的生物技术公司，正在开发和商业化治疗孤儿视网膜疾病的产品。KIO-301 正在开发用于治疗色素性视网膜炎、脉络膜血症和斯塔加特病。它是一种分子光电开关，有可能恢复遗传性和/或年龄相关性视网膜变性患者的视力。KIO-104 正在开发用于治疗后部非感染性葡萄膜炎。它是二氢乳清酸脱氢酶的下一代非甾体免疫调节小分子抑制剂。
In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
除了新闻稿和美国证券交易委员会文件外，我们还希望在我们的网站上发布信息（www.kiorapharma.com）以及可能与投资者相关的社交媒体账户。我们鼓励投资者在推特和领英上关注我们，访问我们的网站和/或订阅电子邮件提醒。
Contacts:
联系人：
Investors
investors@kiorapharma.com
Media
kiora@crowepr.com
Crowe PR
媒体
kiora@crowepr.com
Crowe PR
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/208302
要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/208302
SOURCE Kiora Pharmaceuticals, Inc.
来源 Kiora 制药公司
Released May 8, 2024
2024 年 5 月 8 日发布